HIV-1 integrase inhibitor

Integrase strand transfer inhibitor ( INSTI ) resistance profiles and factors associated with resistance in antiretroviral-naive and -experienced patients failing...


The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection...


Week 48 results from phase III TANGO study were announced. The TANGO study was conducted to assess whether adults living...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...


In the primary analysis of SPRING-2 at week 48, Dolutegravir ( Tivicay ) has shown non-inferior efficacy to and similar...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...


Dolutegravir ( Tivicay ), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. Researchers...


Stribild contains four compounds in a complete once-daily, single tablet regimen: Elvitegravir 150 mg; Cobicistat 150 mg; Emtricitabine 200 mg;...


The FDA ( Food and Drug Administration ) has approved Stribild ( Elvitegravir 150 mg / Cobicistat 150 mg /...